Interrelationships
between serum levels of amiodarone, desethylamiodarone, reverse T3 and the QT interval during long-term amiodarone treatment Amiodarone blocks the peripheral conversion of thyroxine (T4) to tri-iodothyronine (T,),' resulting in increased production of reverse T,. Some investigators2z3 have reported that the increase in the serum reverse T, level which occurs during chronic amiodarone therapy correlates with amiodarone's antiar-rhythmic action. These investigators have suggested that the serum level of reverse T, may be helpful in monitoring long-term amiodarone therapy. Other investigators have demonstrated that amiodarone's antiarrhythmic effect correlates with the serum amiodarone leve1.4-6 Therefore, as is the case with serum levels of reverse T3, serum levels of amiodarone have also been reported as being useful in monitoring amiodarone's efficacy and toxicity. However, the relationship between serum levels of reverse T, and serum levels of amiodarone, or its principal metabolite, desethylamiodarone, has not been reported upon to date. 2. Relationship between serum desethylamiodarone levels and reverse T3 (RT,) levels at 1, 3, and 6 months of treatment. Correlation coefficients and p values are as shown.
The purpose of this study was to determine whether any relationship exists between serum levels of reverse T, and amiodarone or desethylamiodarone during chronic amiodarone therapy. Because either serum reverse T, or serum amiodarone levels may be more conveniently obtained in a particular hospital or community, it would be useful to know if these serum levels can be used interchangeably in following patients being treated with amiodarone. Also examined was the relationship between serum levels of reverse T,, amiodarone, and desethylamiodarone, and an index of amiodarone's cardiac tissue effect, namely prolongation of the QT interval.
METHODS
This study was conducted in 22 patients who were treated with amiodarone for a period of at least 6 months. All patients had normal baseline thyroid function and no clinical evidence of renal or hepatic dysfunction. There were 18 men and 4 women, and their mean age was 53 2 17 years (mean 5 standard deviation). Coronary artery disease was present in 11 patients, valvular heart disease was found in three, and idiopathic dilated cardiomyopathy was seen in one, whereas four patients had no identifiable structural heart disease. The indication for amiodarone therapy in these patients was ventricular tachycardia refractory to conventional antiarrhythmic drugs in 18 patients, and atria1 fibrillation or flutter in four patients.
Before the initiation of therapy with amiodarone, an ECG was obtained at least four half-lives after discontinuation of all antiarrhythmic drugs, as were baseline blood samples for determination of the serum levels of reverse TB, amiodarone, and desethylamiodarone. Amiodarone therapy was initiated at a dose of 1200 mg/day for 1 week, followed by 800 mg/day for 1 month, then 600 mg/day for 1 month; the chronic maintenance dose was 200 to 400 mg/day. An ECG and blood s'amples for determination of the serum levels of amiodarone, desethylamiodarone, and reverse T, were obtained after 1, 3, and 6 months of treatment.
The QT interval was measured from the ECG lead in which termination of the T wave was best defined. The April. same ECG level was used for all QT measurements in each patient. The QT intervals were measured independently by two observers blinded to the serum levels of reverse T, and amiodarone. If the QT measurement differed by more than 0.02 second, differences were resolved by common agreement. The corrected QT interval (QT,) was calculated with Bazett's formu1a.7
Serum levels of reverse T3 were determined by radioimmunoassay. Serum levels of atniodarone and desethylamiodarone were determined with the extraction technique of Storey et al.,8 and the chromatographic conditions of Flanagan et a1.9
Correlation coefficients were determined with a linear regression model. p values of < 0.05 were considered significant.
RESULTS
There was not a significant correlation between serum levels of amiodarone or desethylamiodarone and reverse T3 after either 1, 3, or 6 months of treatment with amiodarone ( Figs. 1 and 2) . There was not a significant correlation between serum levels of reverse T, and AQT, after either 1, 3, or 6 months of treatment with amiodarone (Fig. 3) . Also, there was not a significant correlation between serum levels of amiodarone or desethylamiodarone and AQTC at any of the follow-up intervals (Figs. 4  and 5 ). Expressing AQT, in terms of percent change resulted in no improvement in the above correlations.
DISCUSSION
The results of this study demonstrate that neither serum levels of amiodarone nor desethylamiodarone correlate with the serum level of reverse T, during long-term amiodarone therapy. Therefore, serum levels of reverse T, cannot be used as a substitute for serum levels of amiodarone in monitoring patients being treated with amiodarone (Fig. 6 ). Also of note is the finding that the serum level of reverse T, did not correlate with the degree of amiodarone-induced delay in repolarization, as measured by prolongation of the QT interval. Some investigators have suggested that amiodarone's mechanism of action may involve the induction of a local hypothyroid state in cardiac muscle.2,3 However, the lack of correlation between changes in the QT interval and reverse T, during treatment with amiodarone suggests that the delay in repolarization which occurs with amiodarone is not secondary to an abnormality in thyroid hormone metabolism. Of note is that iopanoic acid, which has effects on thyroid hormone metabolism similar to amiodarone, has been shown to be without ant&rhythmic effects.'O Serum amiodarone or desethylamiodarone levels also did not correlate with changes in the QT interval during long-term treatment with amiodarone. It is unknown whether tissue levels of amiodarone or its metabolite might correlate to a better degree with changes in the QT interval.
This study has several limitations. Firstly, blood samples were drawn at the time of outpatient visits at a variable number of hours after the last dose of amiodarone. However, it is unlikely that this factor significantly affected the results of this study, because Haffajee et al.* reported that there are only minor fluctuations in the serum amiodarone level in the 24-hour dosing interval during maintenance amiodarone therapy. Second, because myocardial tissue levels of amiodarone or desethylamiodarone were not measured, it is unknown whether tissue levels of amiodarone or its metabolite correlate with changes in the QT interval. Third, we were unable to correlate serum drug or reverse T, levels with amiodarone's antiarrhythmic efficacy; the majority of patients in this study had infrequent and sporadic April. 1966 American Heart Journal arrhythmias, and antiarrhythmic efficacy could not be adequately assessed over a 6-month follow-up period.
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